1-2 of 2
Thierry Medts
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

TIM-3 Inhibitor Sabatolimab for Patients with Acute Myeloid Leukemia (AML) with Measurable Residual Disease (MRD) Detected after Allogeneic Stem Cell Transplantation (AlloSCT): Preliminary Findings from the Phase Ib/II Stimulus-AML2 Study

Robert Zeiser, Raynier Devillier, Maria Caterina Mico', David Valcarcel, Simon Call, Christian Niederwieser, Claire Nourry, Yunnan Xu, Thierry Medts, Nathalie Guichard, Hans D. Menssen, Nicola Polverelli
Journal: Blood
Blood (2023) 142 (Supplement 1): 59.
https://doi.org/10.1182/blood-2023-180876
Published: 2023
Journal Articles

Midostaurin in Patients (Pts) with Newly Diagnosed FLT3 -Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial

Jacqueline J Cloos, Pau Montesinos, Walter Fiedler, Rouven Müller, Jürgen Krauter, Simona Sica, Jörg Westermann, Maaike E Heidinga, Lok Lam Ngai, Yvonne J.M Oussoren-Brockhoff, Hartmut Döhner, Mark Levis, Gert J. Ossenkoppele, Richard M. Stone, Giedre Koenen, Bourras-Rezki Bengoudifa, Yuan Cheng, Thierry Medts, Valerie Heidinger, Carolin Sachs, Jorge Sierra
Journal: Blood
Blood (2021) 138 (Supplement 1): 1303.
https://doi.org/10.1182/blood-2021-148129
Published: 2021